[ORGANIZATION]
U.S. Food and Drug Administration (FDA)
Featured in 23 tracked stories · first seen
Situations
GLP-1 drugs: clinical trends, safety, and market shifts
247 clusters · 895 sources · last updated
Latest: GLP-1 medications transform obesity treatment approach
Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr
Taylor Farms manages expanding Cyclospora and Salmonella
50 clusters · 1154 sources · last updated
Latest: US health officials declare end to record cyclosporiasis outbreak
Taylor Farms continues to manage two distinct food safety crises involving Cyclospora and Salmonella. The Cyclospora cayetanensis outbreak, linked to shredded iceberg lettuce from central Mexico, has reached unprecedente
Midwest Egg Recall & Growing Jalapeño Salmonella Outbreak
13 clusters · 175 sources · last updated
Latest: Salmonella outbreak linked to jalapeños affects 431 people in 32 U.S. states
The FDA has maintained a Class I recall for approximately 1.6 million dozen white shell and brown cage-free eggs from Midwest Poultry Services. This highest-risk classification follows a Salmonella Enteritidis outbreak t
Replimune Tudriqev FDA approval and subsequent legal action
5 clusters · 20 sources · last updated
Latest: Replimune faces lawsuits following TUDRIQEV approval
On 6 August 2026, the FDA granted accelerated approval to Replimune’s oncolytic herpes-virus therapy RP1, marketed as Tudriqev, for use with Bristol Myers Squibb’s Opdivo (nivolumab) in adults with unresectable or metast
Moderna mRNA flu vaccine US approval
4 clusters · 68 sources · last updated
Latest: Moderna's mFLUSIVA receives FDA approval as first mRNA flu vaccine
In early August 2026, the U.S. Food and Drug Administration (FDA) authorized Moderna’s mRNA-based seasonal influenza vaccine, mFlusiva. On 6 August, the agency granted full approval for adults aged 50–64, based on a late
US FDA and regulators tighten oversight of peptide compounds
13 clusters · 89 sources · last updated
Latest: US health officials consider relaxing peptide regulations
The FDA’s Pharmacy Compounding Advisory Committee (PCAC) has continued to evaluate injectable synthetic peptides that have surged in the wellness market. After a narrow 8‑6 vote on July 28, 2026, to recommend six of seve
Also covered in
-
US antidepressant users face growing risk of post‑SSRI sexual dysfunction
[HEALTH] · 2 sources ·